ArticleJournal of the Society for Cardiovascular Angiography & Interventions2026
A Hemodynamic Scoring System for Optimizing Transcatheter Arterialization of the Deep Veins in No-Option Patients With Chronic Limb-Threatening Ischemia.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter arterialization of the deep veins (TADV) with LimFlow (Stryker Peripheral Vascular) is an emerging revascularization strategy for patients with high-risk chronic limb-threatening ischemia (CLTI). Variability in outcomes highlights the need for structured tools to guide arteriovenous crossing-site selection and optimize perfusion. We propose an angiographic TADV scoring system to quantify the hemodynamic impact of donor artery selection and evaluate its association with clinical outcomes. Methods: This retrospective analysis included 43 randomly selected patients from the PROMISE II trial with Rutherford class 5 to 6 no-option CLTI. Pre- and postprocedural angiograms were reviewed, and a TADV score (-4 to +4; lower scores indicating worse residual foot perfusion) was calculated by integrating below-the-knee arterial contribution with crossing-site selection. The primary outcome was change in ischemia-related pain. Secondary outcomes included limb salvage, amputation-free survival, wound healing, and secondary patency. Intraclass correlation coefficient assessed score reliability. Linear regression evaluated associations between TADV score and pain, and Cox regression assessed the relationship between pain and major amputation. Results: Technical success was 100%. Mean pain decreased from 5.1 at baseline to 1.4 at 2 years, with median pain reaching 0 by 9 months. At 2 years, limb salvage was 60.7%, amputation-free survival 35.9%, and complete wound healing 62.5%. Intraclass correlation coefficient for the TADV score was 91.7%. Higher TADV scores were associated with lower pain at 1 and 3 months. Each one-point increase in pain increased major amputation risk (hazard ratio, 1.20; 95% CI, 1.02-1.41). Conclusions: The TADV score correlates with early pain reduction and amputation risk, supporting its potential role in optimizing crossing-site selection and outcomes in no-option CLTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.